“…Despite impressive cure rates obtained with modern chemotherapy, the optimal therapeutic strategy in advanced classic Hodgkin Lymphoma (HL) is still debated due to some remaining open issues (Longo, ). These involve the best choice of upfront chemotherapy (Bauer et al , ; Borchmann et al , ; Uhm & Kuruvilla, ), the duration and intensity of frontline treatment (Carde et al , ; Connors, ; Borchmann et al , ), the value of consolidation radiotherapy (Aleman et al , ; Johnson et al , ; Engert et al , ; Terezakis & Kasamon, ), the role of functional imaging in treatment planning and monitoring (Dann et al , ; Avigdor et al , ; Gallamini & Kostakoglu, ) and the adequacy of risk stratification tools (Moccia et al , ; Scott et al , ).…”